[Pharmacokinetics of methohexital given by constant rate intravenous infusion]. 1992

B Bally, and J F Payen, and F Serre-Debeauvais, and B Tranchand, and M Gavend, and P Stieglitz
Département d'Anesthésie-Réanimation, CHU de Grenoble.

The pharmacokinetic characteristics of a constant rate methohexitone infusion were studied in young ASA 1 patients undergoing maxillofacial surgery. They were randomly assigned to two groups; group M patients (n = 7) were given 9 mg.kg-1.h-1 of methohexitone for one hour, and group MF patients (n = 7) 9 mg.kg-1.h-1 of methohexitone with 7 micrograms.kg-1.h-1 of fentanyl, also for one hour. Blood samples for determining methohexitone concentrations were obtained at various times, from before the start of the methohexitone infusion up to 19 h afterwards. In twelve patients, a two-compartment model was appropriate to characterize the decrease of methohexitone concentration; for the other two (one in each group), a three-compartment model was applied. There were no statistically significant differences between the two groups. Elimination half-life in group M was 3.22 +/- 1.96 h, and total plasma clearance 8.54 +/- 2.8 ml.kg-1.min-1. The wide variations in pharmacokinetic parameters between subjects may explain some unpredictable variations in duration of action of methohexitone. Fentanyl did not modify methohexitone pharmacokinetics, which remained of the first order. However, it potentiated the barbiturate's action: extubation was only possible after stopping the infusion for 39.4 min +/- 22 min in group MF, and 15.4 min +/- 6 min in group M (p less than 0.01). At that time, plasma concentrations were respectively 3.12 +/- 0.99 mg.l-1 (group MF) and 5.71 +/- 2.09 mg.l-1 (group M), (p less than 0.05).(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D008297 Male Males
D008723 Methohexital An intravenous anesthetic with a short duration of action that may be used for induction of anesthesia. Methohexitone,Brevimytal Natrium,Brevital,Brietal,Brietal-Sodium,Methohexital Sodium,Methohexital, Monosodium Salt,Brietal Sodium,Monosodium Salt Methohexital,Natrium, Brevimytal,Sodium, Methohexital
D011446 Prospective Studies Observation of a population for a sufficient number of persons over a sufficient number of years to generate incidence or mortality rates subsequent to the selection of the study group. Prospective Study,Studies, Prospective,Study, Prospective
D004357 Drug Synergism The action of a drug in promoting or enhancing the effectiveness of another drug. Drug Potentiation,Drug Augmentation,Augmentation, Drug,Augmentations, Drug,Drug Augmentations,Drug Potentiations,Drug Synergisms,Potentiation, Drug,Potentiations, Drug,Synergism, Drug,Synergisms, Drug
D005260 Female Females
D005283 Fentanyl A potent narcotic analgesic, abuse of which leads to habituation or addiction. It is primarily a mu-opioid agonist. Fentanyl is also used as an adjunct to general anesthetics, and as an anesthetic for induction and maintenance. (From Martindale, The Extra Pharmacopoeia, 30th ed, p1078) Phentanyl,Duragesic,Durogesic,Fentanest,Fentanyl Citrate,Fentora,R-4263,Sublimaze,Transmucosal Oral Fentanyl Citrate,R 4263,R4263
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

B Bally, and J F Payen, and F Serre-Debeauvais, and B Tranchand, and M Gavend, and P Stieglitz
July 1990, British journal of clinical pharmacology,
B Bally, and J F Payen, and F Serre-Debeauvais, and B Tranchand, and M Gavend, and P Stieglitz
July 2006, Veterinary anaesthesia and analgesia,
B Bally, and J F Payen, and F Serre-Debeauvais, and B Tranchand, and M Gavend, and P Stieglitz
October 1987, British journal of clinical pharmacology,
B Bally, and J F Payen, and F Serre-Debeauvais, and B Tranchand, and M Gavend, and P Stieglitz
January 1994, Journal of clinical anesthesia,
B Bally, and J F Payen, and F Serre-Debeauvais, and B Tranchand, and M Gavend, and P Stieglitz
January 1982, European journal of clinical pharmacology,
B Bally, and J F Payen, and F Serre-Debeauvais, and B Tranchand, and M Gavend, and P Stieglitz
December 2023, BMC veterinary research,
B Bally, and J F Payen, and F Serre-Debeauvais, and B Tranchand, and M Gavend, and P Stieglitz
November 1989, European journal of anaesthesiology,
B Bally, and J F Payen, and F Serre-Debeauvais, and B Tranchand, and M Gavend, and P Stieglitz
May 1981, Journal of pharmaceutical sciences,
B Bally, and J F Payen, and F Serre-Debeauvais, and B Tranchand, and M Gavend, and P Stieglitz
August 1995, Biopharmaceutics & drug disposition,
B Bally, and J F Payen, and F Serre-Debeauvais, and B Tranchand, and M Gavend, and P Stieglitz
June 1988, Transplantation proceedings,
Copied contents to your clipboard!